URGN Stock Analysis: Buy, Sell, or Hold?
URGN - UroGen Pharma Ltd. Ordinary Shares
$38.59
0.35 (0.92%)
▲
5d:
-6.92%
30d:
+1.5%
90d:
+67.78%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
TODAY
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: URGN is fairly valued with market pricing in 3.6% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: URGN is fairly valued with market pricing in 3.6% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$48.77
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$30.28
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $38.59, which is considered fair relative to its 30-day fair value range of $37.37 to $41.49. From a valuation perspective, the stock is trading at a premium (Forward PE: 25.8) compared to its historical average (23.3). At these levels, the market is pricing in 3.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $36.68, while resistance sits at $43.93.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.75 (+16.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $36.68, while resistance sits at $43.93.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.75 (+16.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$37.37 -
$41.49
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
76.5%
Protect Your Profits
Holding URGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($44.75)
- NEUTRAL: Market pricing in 3.6% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -6.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$37.37 -
$41.49
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$5.10
(13.2%)
Support & Resistance Levels
Support Level
$36.68
Resistance Level
$43.93
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
25.83
Wall Street Target
$44.75
(+16.0%)
Revenue Growth (YoY)
151.6%
Profit Margin
-94.8%
Valuation Premium vs History
+3.6% premium
PE vs Historical
25.8 vs 23.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$39.98
(+4%)
2-Year Target
$41.42
(+7%)
3-Year Target
$42.91
(+11%)
3-Yr Target (if PE normalizes)
(PE: 26→23)
PE COMPRESSION
$38.70
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 04, 2026 3:49 AM ET
Data refreshes hourly during market hours. Next update: 4:49 AM
Data refreshes hourly during market hours. Next update: 4:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
